Two Markets, Two Fates: Why Branded Generics Dominate Emerging Economies and Get Crushed in the US
Branded generics — off-patent drugs sold under a proprietary name rather than an INN — are a $280 billion global […]
The Oral-to-Injectable Flip: How to Use Patent Gaps to Reinvent a Therapy Class
The compound is twenty years old. The molecule patent expires in eighteen months. Forty ANDA filers are lined up. The
The Oral-to-Injectable Flip: How to Use Patent Gaps to Reinvent a Therapy Class Read Post »
Reformulation: Pharma’s Best Defense Against Generic Commoditization
When a brand-name drug loses patent protection, it typically sheds 80% of its revenue within 12 months. That is not
Reformulation: Pharma’s Best Defense Against Generic Commoditization Read Post »
Stop Copying Molecules: Patent Drug Delivery Systems Instead
How the smartest pharmaceutical IP teams build exclusivity that outlasts the molecule by a decade — and what happens when
Stop Copying Molecules: Patent Drug Delivery Systems Instead Read Post »
Off-Patent Molecules, On-Patent Combinations: The DrugPatentWatch Playbook for Finding Formulation Gold
There is a class of pharmaceutical asset that rarely shows up in earnings calls but drives billions in brand revenue
The FDC Patent Goldmine: How Two Expired Patents Can Equal One New One
Somewhere in a brand-name drug company’s lifecycle management plan, there is usually a line item that reads something like: ‘Evaluate
The FDC Patent Goldmine: How Two Expired Patents Can Equal One New One Read Post »
The FDA Orange Book Is Dead Weight: The New Pharmaceutical Patent Intelligence Playbook
The FDA Orange Book publishes patent expiry dates. Analysts read them, model them into revenue forecasts, and brief executives on
The FDA Orange Book Is Dead Weight: The New Pharmaceutical Patent Intelligence Playbook Read Post »
NCE-1 Dates Are Your Best Sales Lead: The API Supplier’s Definitive Guide to Generic Drug Pipeline Intelligence
How to turn a single FDA regulatory date into a structured, repeatable, competitively timed sales funnel for active pharmaceutical ingredient
Authorized Generics: The Real Reason Brands Launch Them (It’s Not Confidence)
When a pharmaceutical brand launches an authorized generic, the press release typically says something about “patient access” or “expanding options.”
Authorized Generics: The Real Reason Brands Launch Them (It’s Not Confidence) Read Post »
